The Association of Nighttime Fasting Duration and Prostate Cancer Risk: Results from the Multicase-Control (MCC) Study in Spain
Por:
Palomar-Cros A, Espinosa A, Straif K, Pérez-Gómez B, Papantoniou K, Gómez-Acebo I, Molina-Barceló A, Olmedo-Requena R, Alguacil J, Fernández-Tardón G, Casabonne D, Aragonés N, Castaño-Vinyals G, Pollán M, Romaguera D and Kogevinas M
Publicada:
1 ago 2021
Ahead of Print:
30 jul 2021
Resumen:
Nighttime fasting has been inconclusively associated with a reduced risk of cancer. The purpose of this study was to investigate this association in relation to prostate cancer risk. We examined data from 607 prostate cancer cases and 848 population controls who had never worked in night shift work from the Spanish multicase-control (MCC) study, 2008-2013. Through an interview, we collected circadian information on meal timing at mid-age. We estimated odds ratios (OR) and 95% confidence intervals (CI) with unconditional logistic regression. After controlling for time of breakfast, fasting for more than 11 h overnight (the median duration among controls) was associated with a reduced risk of prostate cancer compared to those fasting for 11 h or less (OR = 0.77, 95% 0.54-1.07). Combining a long nighttime fasting and an early breakfast was associated with a lower risk of prostate cancer compared to a short nighttime fasting and a late breakfast (OR = 0.54, 95% CI 0.27-1.04). This study suggests that a prolonged nighttime fasting duration and an early breakfast may be associated with a lower risk of prostate cancer. Findings should be interpreted cautiously and add to growing evidence on the importance of chrononutrition in relation to cancer risk.
Filiaciones:
Palomar-Cros A:
Barcelona Institute for Global Health (ISGlobal), 08003 Barcelona, Spain
Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
Espinosa A:
Barcelona Institute for Global Health (ISGlobal), 08003 Barcelona, Spain
Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, 28029 Madrid, Spain
Straif K:
Barcelona Institute for Global Health (ISGlobal), 08003 Barcelona, Spain
Pérez-Gómez B:
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, 28029 Madrid, Spain
National Centre for Epidemiology, Carlos III Institute of Health, 28029 Madrid, Spain
Papantoniou K:
Department of Epidemiology, Centre of Public Health, Medical University of Vienna, 1090 Vienna, Austria
Gómez-Acebo I:
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, 28029 Madrid, Spain
Facultad de Medicina, Universidad de Cantabria-IDIVAL, 39011 Santander, Spain
:
Cáncer y Salud Pública, FISABIO, 46020 Valencia, Spain
Olmedo-Requena R:
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, 28029 Madrid, Spain
Department of Preventive Medicine and Public Health, Universidad de Granada, 18016 Granada, Spain
Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, 18014 Granada, Spain
Alguacil J:
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, 28029 Madrid, Spain
Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Campus Universitario de El Carmen, 21071 Huelva, Spain
Fernández-Tardón G:
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, 28029 Madrid, Spain
Instituto de Investigación Sanitaria del Principado de Asturias (ISPA) and IUOPA, Universidad de Oviedo, 33006 Oviedo, Spain
Cancer Epidemiology Research Programme IDIBELL, Institut Català d'Oncologia, 08908 L'Hospitalet de Llobregat, Spain
Casabonne D:
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, 28029 Madrid, Spain
Cancer Epidemiology Research Programme IDIBELL, Institut Català d'Oncologia, 08908 L'Hospitalet de Llobregat, Spain
Aragonés N:
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, 28029 Madrid, Spain
National Centre for Epidemiology, Carlos III Institute of Health, 28029 Madrid, Spain
Castaño-Vinyals G:
Barcelona Institute for Global Health (ISGlobal), 08003 Barcelona, Spain
Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, 28029 Madrid, Spain
Pollán M:
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, 28029 Madrid, Spain
National Centre for Epidemiology, Carlos III Institute of Health, 28029 Madrid, Spain
Romaguera D:
Barcelona Institute for Global Health (ISGlobal), 08003 Barcelona, Spain
Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), 28029 Madrid, Spain
Kogevinas M:
Barcelona Institute for Global Health (ISGlobal), 08003 Barcelona, Spain
Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, 28029 Madrid, Spain
Green Published, gold
|